The company has announced a one-for-thirty reverse stock split of its common shares.
This action is intended to regain compliance with the Nasdaq Capital Market's minimum bid price requirement of one dollar per share.
The split, approved by shareholders and the board of directors, will take effect at the opening of trading on June 4, 2026, with the company's shares trading on a split-adjusted basis under the existing ticker symbol ICCM.
IceCure Medical Ltd. (NASDAQ: ICCM)
IceCure Medical is an Israel-based medical device company focused on cryoablation technology.
Its core ProSense system uses liquid nitrogen to freeze and destroy tumors and has received regulatory approvals in multiple global markets for treating benign and malignant lesions in areas such as the breast, kidney, lung, and liver.
In October 2025, the company secured U.S. Food and Drug Administration marketing authorization to expand the system's indications to include select older, low-risk breast cancer patients, subsequently earning a recommendation in the latest guidelines from the American Society of Breast Surgeons.
According to its first-quarter 2026 financial results, the company's global revenue increased by 26% year-over-year.
Growth in the North American market reached 84%, with U.S. growth at 31%.
The company attributes this growth primarily to initial increases in market penetration for its core product following the FDA authorization.
The reverse stock split is a proactive measure to address the risk of delisting due to the stock's sustained trading below the one-dollar threshold.
The company is required to resolve this compliance issue by November 9, 2026.
The reverse split will reduce the number of issued and outstanding common shares from approximately 84.2 million to about 2.8 million.
The split will not alter shareholders' percentage ownership, although fractional shares will be rounded up.
Eyal Shamir, Chief Executive Officer of IceCure, stated that the company believes implementing this reverse split is a strategic step to ensure its continued listing on Nasdaq.
He emphasized that maintaining this listing is crucial for preserving stock liquidity and access to capital markets.
With the company's business momentum continuing positively, upholding a compliant status with listing standards will better support the execution of its long-term growth strategy and maximize shareholder value.
Comments